ストックスクリーナーアプリを入手
36.52
1.62%
-0.60
前日終値:
$37.12
開ける：
$37.49
24時間の取引高:
2.65M
Relative Volume:
2.75
時価総額：
$3.55B
収益：
$522.75M
当期純損益:
$-558.99M
株価収益率:
-5.6445
EPS:
-6.47
ネットキャッシュフロー:
$-439.53M
1週間 パフォーマンス:
-1.67%
1か月 パフォーマンス:
+4.10%
6か月 パフォーマンス:
-15.89%
1年 パフォーマンス:
-11.83%
1日の値動き範囲:
$35.59
$38.19
1週間の範囲:
$35.59
$38.19
52週間の値動き範囲:
$29.59
$60.37
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
名前
Ultragenyx Pharmaceutical Inc
セクター
電話
415-483-8800
住所
60 LEVERONI COURT, NOVATO, CA
RARE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
36.52 | 3.55B | 522.75M | -558.99M | -439.53M | -6.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.30 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.83 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.14 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
241.20 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-28 | 開始されました | William Blair | Outperform |
| 2024-06-06 | アップグレード | Goldman | Neutral → Buy |
| 2024-04-22 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2023-06-14 | 再開されました | Credit Suisse | Outperform |
| 2023-06-06 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-04-26 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-01-18 | 再開されました | Canaccord Genuity | Buy |
| 2022-12-30 | 再開されました | H.C. Wainwright | Buy |
| 2022-11-03 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2022-10-13 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-08-01 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-03-16 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2022-02-11 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-09-30 | 開始されました | H.C. Wainwright | Buy |
| 2021-08-19 | 開始されました | UBS | Sell |
| 2021-07-15 | 開始されました | Guggenheim | Neutral |
| 2021-06-29 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-06-04 | 再開されました | Robert W. Baird | Neutral |
| 2021-05-06 | アップグレード | Citigroup | Neutral → Buy |
| 2021-05-06 | アップグレード | Evercore ISI | In-line → Outperform |
| 2021-04-26 | 再開されました | Credit Suisse | Neutral |
| 2021-03-02 | 再開されました | Stifel | Buy |
| 2021-02-12 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-12-07 | ダウングレード | Wedbush | Outperform → Neutral |
| 2020-11-24 | 再開されました | Evercore ISI | In-line |
| 2020-11-12 | ダウングレード | BofA Securities | Buy → Neutral |
| 2019-08-02 | 再開されました | Wedbush | Outperform |
| 2019-03-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2019-02-22 | 再開されました | Raymond James | Outperform |
| 2019-01-02 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2018-11-08 | アップグレード | Citigroup | Sell → Neutral |
| 2018-09-10 | 開始されました | Morgan Stanley | Equal-Weight |
| 2018-06-21 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2018-05-11 | アップグレード | Barclays | Equal Weight → Overweight |
| 2018-05-10 | 開始されました | Goldman | Neutral |
| 2018-04-18 | アップグレード | SunTrust | Hold → Buy |
| 2018-03-22 | 再開されました | Piper Jaffray | Overweight |
| 2018-02-21 | 繰り返されました | Stifel | Buy |
| 2018-01-22 | アップグレード | Evercore ISI | In-line → Outperform |
| 2018-01-18 | 開始されました | Credit Suisse | Outperform |
| 2017-12-05 | 繰り返されました | Barclays | Equal Weight |
| 2017-12-04 | アップグレード | Jefferies | Hold → Buy |
| 2017-09-14 | アップグレード | Wedbush | Neutral → Outperform |
すべてを表示
Ultragenyx Pharmaceutical Inc (RARE) 最新ニュース
Exploring the Road Ahead: X-linked Hypophosphatemia Market - openPR.com
(RARE) Long Term Investment Analysis - news.stocktradersdaily.com
Ultragenyx’s SWOT analysis: rare disease biotech stock faces pivotal year By Investing.com - Investing.com Canada
Ultragenyx’s SWOT analysis: rare disease biotech stock faces pivotal year - Investing.com Australia
FDA approves Ultragenyx's Mepsevii in mucopolysaccharidosis type VII enzyme disorder - FirstWord Pharma
Transcript : Ultragenyx Pharmaceutical Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 10 - MarketScreener
Ultragenyx (RARE) Q1 2025 Performance Shows Resilience - GuruFocus
Ultragenyx reports 28% rise in Q1 revenue from year ago - The Press Democrat
Ultragenyx (RARE) Up 9.6% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Mucopolysaccharidosis III Pipeline 2025: Groundbreaking - openPR.com
How the (RARE) price action is used to our Advantage - news.stocktradersdaily.com
Ultragenyx to Participate at Goldman Sachs 46th Annual Global He - GuruFocus
Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference | RARE Stock News - GuruFocus
Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewswire
Ultragenyx CEO Reveals Latest Rare Disease Breakthroughs at Goldman Sachs Healthcare Conference - Stock Titan
Adeno-Associated Virus (AAV) Vectors in Gene Therapy Pipeline - openPR.com
William Blair Initiates Coverage of Ultragenyx Pharmaceutical (BMV:RARE) with Outperform Recommendation - Nasdaq
Ultragenyx Pharmaceutical (NASDAQ:RARE) Coverage Initiated by Analysts at William Blair - Defense World
William Blair Initiates Coverage of Ultragenyx Pharmaceutical (LSE:0LIF) with Outperform Recommendation - Nasdaq
William Blair Initiates Coverage of Ultragenyx Pharmaceutical (RARE) with Outperform Recommendation - MSN
William Blair sets Ultragenyx stock at Outperform with $65 target By Investing.com - Investing.com Australia
What 4 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical - Benzinga
Analyst Bullish On Ultragenyx, Poised For Growth With Six Drug Approvals Expected By 2028 - Benzinga
Ultragenyx Pharmaceutical (RARE) Receives New Coverage with 'Out - GuruFocus
Ultragenyx Pharmaceutical (RARE) Receives New Coverage with 'Outperform' Rating | RARE Stock News - GuruFocus
William Blair Initiates Ultragenyx Pharmaceutical at Outperform - marketscreener.com
William Blair sets Ultragenyx stock at Outperform with $65 target - Investing.com
Ultragenyx (RARE) Gains Outperform Rating with $65 Target | RARE Stock News - GuruFocus
Sanfilippo syndrome Pipeline 2025: Groundbreaking Clinical - openPR.com
Ultragenyx’s SWOT analysis: rare disease biotech stock poised for growth By Investing.com - Investing.com Nigeria
Ultragenyx’s SWOT analysis: rare disease biotech stock poised for growth - Investing.com
CDKL5 Deficiency Disorder Market Expected to Experience Major - openPR.com
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 56 - GuruFocus
Ultragenyx Grants $4.5M in Stock Awards: 20 New Hires Receive Retention Packages - Stock Titan
Ultragenyx Pharmaceutical Approves Key Proposals at Annual Meeting - MSN
Ultragenyx Underscores Continued Commitment to Rare Disease Inno - GuruFocus
Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report - GlobeNewswire
Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report | RARE Stock News - GuruFocus
(RARE) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Transcript : Ultragenyx Pharmaceutical Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 08 - marketscreener.com
Glycogen Storage Disease Treatment Market Size in 7MM - openPR.com
Ultragenyx Pharmaceutical Inc (RARE) 財務データ
収益
当期純利益
現金流量
EPS
1.11%
1.70%
大文字化:
|
ボリューム (24 時間):